Source: Annual Congress 2006 - COPD - assessment and prognosis
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Vestbo, C. Harvey, D. Ffyona, L. David, M. William, S. Edwin, on Behalf of the ECLIPSE Investigators (Copenhagen, Denmark; Vancouver, Canada; London, Cambridge, Edinburgh, United Kingdom; Boston, United States Of America). Evaluation of COPD longitudinally to identify predictive surrogate endpoints (ECLIPSE). Eur Respir J 2006; 28: Suppl. 50, 4679

Member's Comments

No comment yet.

Related content which might interest you: Blood biomarkers in COPD: results from the ECLIPSE (evaluation of COPD longitudinally to identify predictive surrogate endpoints) cohort Source: Annual Congress 2009 - Biomarkers, comorbidities and prognosis of COPD Year: 2009 SGRQ-C distribution in the evaluation of COPD longitudinally to identify predictive surrogate endpoints (ECLIPSE) cohort: Characteristics of COPD subjects with extreme score quintiles Source: Annual Congress 2010 - COPD: symptoms and staging Year: 2010 External validation of two prognostic scores predicting exacerbations in ECLIPSE COPD patients Source: Virtual Congress 2020 – Airflow obstruction, COPD and comorbidities Year: 2020 COPD related fatigue (COPD-RF) as a patient centred outcome tool in COPD: Various predictors and its correlation with other outcome parameters Source: International Congress 2016 – Monitoring airway diseases with clinical tools Year: 2016 Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) Source: Eur Respir J 2008; 31: 869-873 Year: 2008 Mortality risk prediction in COPD by a prognostic biomarker panel – Results of a derivation and validation cohort with a long term follow-up Source: International Congress 2014 – Markers Year: 2014 Novel patterns of serum biomarkers profiling using minimal important clinical outcomes (MICO) in the longidutinal study BODE cohort of COPD patients Source: Annual Congress 2010 - COPD: symptoms and staging Year: 2010 LATE-BREAKING ABSTRACT: Biomarkers of tissue turnover are related to annual change in FEV1 in patients with COPD within the ECLIPSE cohort Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015 Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort Source: Eur Respir J 2013; 42: 636-646 Year: 2013 Heterogeneity in the clinical outcomes of COPD: lessons from the ECLIPSE study Source: International Congress 2017 – Heterogeneity in COPD inflammation: implications for therapy and clinical outcomes Year: 2017 LATE-BREAKING ABSTRACT: Biomarkers of extracellular matrix turnover predict mortality in the ECLIPSE COPD cohort Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015 Identification of distinct trajectories of FEV1 progression in the ECLIPSE cohort Source: Virtual Congress 2021 – Deep phenotyping of obstructive diseases for precision medicine Year: 2021 Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis Source: ERJ Open Res, 7 (1) 00663-2020; 10.1183/23120541.00663-2020 Year: 2021 Possible cut-off values for stable or instable COPD as measured by the clinical COPD questionnaire (CCQ) Source: Annual Congress 2011 - Quality of life and respiratory symptom management in primary care Year: 2011 Predictive value of multiorgan imaging biomarkers for predicting exacerbations in COPD patients Source: International Congress 2018 – Biomarkers of COPD and asthma-COPD overlap syndrome (ACOS) Year: 2018 CAT (COPD assessment test) as outcome parameter of pulmonary rehabilitation (PR) in COPD Source: Annual Congress 2011 - What do individuals know about their disease? Educational needs, the psychological impact of chronic respiratory disease and health-related quality of life Year: 2011 Longitudinal change of COPD assessment test (CAT) in a telehealthcare cohort is associated with exacerbation risk Source: International Congress 2017 – Current challenges in COPD evaluation Year: 2017 Clinical prognostic tools and their use in COPD. Source: Virtual Congress 2020 – Clinical and functional evaluation of COPD Year: 2020 FEV6: a useful outcome measure of lung function in COPD as assessed in a large clinical study with roflumilast Source: Eur Respir J 2004; 24: Suppl. 48, 342s Year: 2004 Stability of serum biomarkers and their associations with clinical outcomes in COPD patients and controls: a longitudinal study Source: Annual Congress 2009 - Biomarkers and biology in COPD Year: 2009